Benzinga

OCTOBER 19, 2023

("Tourmaline") (NASDAQ: TRML ), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced the completion of its previously announced merger with Talaris Therapeutics, Inc.

Marketability 45

Marketability 45

Benzinga

FEBRUARY 23, 2023

Combined company will be focused on advancing Enliven's clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol "ELVN" on February 24, 2023 Combined company is expected to have cash runway into early 2026 BOULDER, Colo., 23, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc.

Marketability 40

Marketability Finance 40

Benzinga

OCTOBER 13, 2022

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programs. Combined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026.

Finance 40

Finance Marketability 40

Benzinga

APRIL 11, 2024

The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy. NASDAQ: ELYM ) ("Eliem") and Tenet Medicines, Inc.

Marketability 40

Marketability 40

Benzinga

JUNE 22, 2023

8 million and approximately 21.3 % of the combined company BOSTON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. 8 million and approximately 21.3 % of the combined company BOSTON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. NASDAQ: TALS ) ("Talaris") and Tourmaline Bio, Inc.

Dividends 40

Dividends Finance 40

Benzinga

OCTOBER 1, 2022

- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -. Companies to Host Conference Call today, September 30, 2022 at 8:00 AM ET -. . Companies to Host Conference Call today, September 30, 2022 at 8:00 AM ET -.

Finance 40

Finance Marketability 40